leadf
logo-loader
AIM:SAR FRA:RYH

Sareum Holdings PLC

Receive alerts
Market:
AIM
Market Cap:
£56.37 m
Price
1.73 GBX
Change
1.47%
52 weeks high
3.09
52 weeks low
0.22

Our strategy

Sareum’s strategy is to develop programmes to late preclinical or early clinical stages to take advantage of the higher asset values associated with licensing programmes at these stages.

Discovery

Overview

Sareum's pipeline is built on the drug discovery expertise of its founders, particularly in the field of small molecule kinase inhibitors.

Sareum operates a collaborative and outsourced business model. All our laboratory-based research is carried out in the laboratories of collaborators or third-party providers. This enables us to access drug discovery expertise throughout the world with a very flexible cost base.

TYK2/JAK1 - Covid-19

The aim of Sareum’s Covid-19 research programme is to investigate the effects of SDC-1801 on cytokine signalling after human cells are infected with SARS-CoV-2, to confirm whether an over-active inflammatory response (known as a ‘cytokine storm’) via the Interferon Type 1 pathway can be blocked in this disease. The company will also investigate whether treatment with SDC-1801 in disease models can re-establish protection against bacterial pneumonia following SARS-CoV-2 infection.

Drug discovery

Sareum’s drug discovery focuses on targeted small molecule therapeutics.  These are designed to disrupt the biochemical processes that drive the growth of cancers and development of auto-immune diseases. 

Discovery platform

Sareum’s SKIL® (Sareum Kinase Inhibitor Library) discovery platform is based on a chemical template which can be adapted to inhibit many different kinases. SKIL compounds demonstrate high potency with good selectivity. Lead compounds have been developed that are suitable for i.v. or oral administration.

Other programmes

We have developed intellectual property in several early stage discoveries. Research on these is currently on hold while we invest in our more advanced development programmes.

Development

Cancer – Chk1 kinase

Checkpoint Kinase 1 (Chk1) is Sareum's most advanced programme. It was discovered and advanced into first clinical trials in collaborations with the Institute of Cancer Research and the CRT Pioneer Fund, then licensed to Sierra Oncology Inc. (NASDAQ: SRRA) in September 2016. Sierra is now responsible for progressing the candidate drug through clinical trials and to the market. The clinical candidate drug, SRA737 (formerly CCT245737), and other lead series compounds have shown strong potency in numerous cancer models.

Autoimmune - TYK2/JAK1 kinases

TYK2 and JAK1 are members of the Janus Kinase (JAK) family of protein kinase enzymes with roles in pro-inflammatory responses in autoimmune diseases and tumour cell proliferation in certain cancers. Members of the JAK family are the targets of several marketed and clinical-stage drugs for cancer and autoimmune diseases, although there are currently no marketed products specifically targeting TYK2. 

Cancer - TYK2/JAK1 kinases

Sareum's TYK2/JAK1 preclinical development candidate molecule, SDC-1802, demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. In addition, Sareum has generated encouraging evidence to suggest that these molecules can function as cancer immunotherapy by modulating the host’s immune system to block tumour cell proliferation in disease models of certain kidney, colon, skin and pancreatic cancers.

Cancer – FLT3+Aurora kinases

Sareum's FLT3+Aurora Kinase programme targets Acute Myeloid Leukaemia (AML) and other blood cancers. The programme is currently undergoing preclinical studies. We plan to use the data from these studies to prepare an application to undertake clinical studies in cancer patients.

 United Kingdom

Stephen Parker - Non-Executive Chairman

Dr Stephen Parker, aged 60, has a career in the healthcare and pharma sector that spans over 30 years, including six years in the City in advisory roles. He has sector corporate finance experience having been an investment banker focusing on pharma and biotechnology with Barings, Warburg and Apax Partners and has previously held roles as a partner at Celtic Pharma and Chief Financial Officer of Oxford GlycoSciences. Stephen is also a Non-executive Director at MGC Pharma.

Tim Mitchell - Founder and CEO

Dr Tim Mitchell, aged 58, has a wide breadth of management, business and research expertise gained over 30 years in the biotech, large pharmaceutical and research service companies.

He is the inventor of Oblean® (cetilistat) for which Takeda have obtained sales approval in the Japanese market for the treatment of obesity with complications.

Prior to co-founding Sareum he was Director of Structure-Based Discovery at Millennium Pharmaceuticals, Director of Computational Chemistry at Cambridge Discovery Chemistry, and Team Leader at SmithKline Beecham Pharmaceuticals. Tim has a PhD in Computational Chemistry and a BSc in Chemistry.

John Reader - Founder and CSO

Dr John Reader, aged 52, has over 25 years' experience within the industry. His previous roles include Associate Director, Chemical Technologies at Millennium Pharmaceuticals Research and Development Ltd, Pharmacopeia Inc., and Cambridge Discovery Chemistry.

John has an excellent track record of delivering successful drug research projects. He has authored or co-authored many publications and patents on small molecule drug discovery. John is a member of the EPSRC Peer Review College and has a PhD in Chemistry and a BSc in Applied Chemistry.

Michael Owen - Non-Executive Director

Dr Michael Owen, aged 67, has worked in biomedical research, and in the pharmaceutical and biotechnology industries for nearly 40 years. He is the co-founder and first CSO of Kymab Ltd, a biopharmaceutical company based in Cambridge, UK, prior to which he worked for GSK where he was SVP and Head of Research for Biopharmaceuticals R&D. Dr Owen currently serves on the boards of several public and private biotechnology companies in the UK, Europe and the USA, including Avacta Group plc, ReNeuron plc, GammaDelta Therapeutics and Zealand Pharma A/S. He is also the Chairman of Ossianix Inc. In addition, Dr Owen is Chairman of ReNeuron’s and Avacta’s scientific advisory boards, an advisor to Abingworth LLP and was until recently an advisor to the CRT Pioneer Fund. Dr Owen received a MA from Oxford University and a PhD from Cambridge University, and is an elected member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences.

Clive Birch - Non-Executive Director

Clive Birch, aged 65, is an Independent Non-Executive Director of Cambridge Innovation Capital plc, a Cambridge-based builder of technology and healthcare companies. He is a retired partner of PricewaterhouseCoopers where his role was that of an auditor and reporting accountant with an industry specialism in early stage technology and healthcare companies. He was also part of the teams involved in fund raising and listing those clients on various markets. Mr Birch was also partner in charge of PwC’s Cambridge office for 15 years up to 2010, during which time he was responsible for all aspects of that stand-alone business. Mr Birch is a Governor of Birkbeck College, part of London University.

Head office

Sareum Limited.
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge
CB22 3FX
United Kingdom

tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
email: info@sareum.co.uk

Registered in England No. 4863659

Hybridan LLP
20 Ironmonger Lane
London
EC2V 8EP
www.hybridan.com

Nominated & Financial Adviser

Strand Hanson Limited
26 Mount Row
London
W1K 3SQ
www.strandhanson.co.uk

Directors and Significant Shareholders:

Last updated 23-October-2020.

Head office

Sareum Limited.
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge
CB22 3FX
United Kingdom

Broker

Hybridan LLP
20 Ironmonger Lane
London
EC2V 8EP
www.hybridan.com

Nominated & Financial Adviser

Strand Hanson Limited
26 Mount Row
London
W1K 3SQ
www.strandhanson.co.uk

Registrars

Link Asset Services
34 Beckenham Rd
Beckenham
Kent
BR3 4TU
www.linkassetservices.com

Solicitors

Taylor Vinters
Merlin Place
Milton Road
Cambridge
CB4 0DP
www.taylorvinters.com

Auditor

Shipleys LLP
10 Orange Street
London
WC2H 7DQ
www.shipleys.com

Financial PR

Citigate Dewe Rogerson
26 Southampton Buildings
London
WC2A 1AN
www.citigatedewerogerson.co.uk